Navigation Links
BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital in Biomarker Research for Personalized Cancer Therapies

MADRID, Nov. 16, 2011 /PRNewswire/ -- The BBVA Foundation announced an agreement to underwrite a joint effort between Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital to search for personalized cancer therapies through biomarker research.

The BBVA Foundation Tumor Biomarkers Research Program will provide 2.5 million euros over the next five years to fund the collaborative efforts of MGH and VHIO.  MGH has also committed to match up to 1.25 million euros of the BBVA Foundation contribution.  Funding for the research may be increased according to economic circumstances and as need arises.

"We are grateful that the BBVA Foundation is not only maintaining but boosting its support for this program, along with its broader commitment to research in general, and cancer research in particular, at a time of economic difficulties," said Josep Baselga, chief of hematology/oncology at MGH.

BBVA Foundation President Francisco Gonzalez concurred, adding: "Spain cannot afford to slip behind in an area where it has already attained a position of some prominence, and where research results can drive tangible improvements in the diagnostic and therapeutic options available to patients."  

BBVA Foundation President and BBVA CEO Francisco Gonzalez, Josep Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center, and Andres de Kelety, managing director at the Vall d'Hebron Institute of Oncology signed the agreement creating the program Monday in Barcelona. Also attending the event was the BBVA Foundation Director Rafael Pardo.

Biomarkers are biological characteristics of malignant cells that are measurable in tumor tissue and, at times, in blood. Biomarkers can measure alterations of the genome, of the proteins encoded by the genome and at times enzymes or metabolites. The information they give can be prognostic – how the disease is likely to evolve – or predictive – how it may respond to a given treatment. Studies in this case will initially center on colorectal, breast and lung cancer, with likely expansion into melanomas, lymphomas, and prostate cancer.

For more information on the BBVA Foundation, please visit

SOURCE BBVA Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
2. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
3. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
4. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
5. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. GBS/CIDP Foundation to Hold 10th International Symposium
8. Mirixa Corporation and the APhA Foundation Form Partnership
9. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
10. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
11. Canary Foundations Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):